The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program
Related Resources
All Resources
post
Navigating Regulatory Affairs for Clinical Trials
Read More
webinar
Don’t Derail Drug Development: Common Issues to Identify and Avoid with a First-Rate Quality Process
Read More
infographic
Benefits of Orphan Drug Designation by the Numbers Infographic
Read More
infographic
Avoid Drug Development Derailment Infographic
Read More
Let's move from science to success.
Let’s Talk